135 related articles for article (PubMed ID: 37680021)
1. Benefits of rIX-FP prophylaxis in patients with Haemophilia B: real-world evidence from a Spanish reference centre.
Benítez-Hidalgo O; Bosch Schips M; Juárez Giménez JC; Gironella M
Hematology; 2023 Dec; 28(1):2242656. PubMed ID: 37680021
[TBL] [Abstract][Full Text] [Related]
2. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
[TBL] [Abstract][Full Text] [Related]
3. IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy.
Tagliaferri A; Molinari AC; Peyvandi F; Coppola A; Demartis F; Biasoli C; Borchiellini A; Cultrera D; De Cristofaro R; Daniele F; Giordano P; Marchesini E; Margaglione M; Marino R; Pollio B; Radossi P; Santoro C; Santoro RC; Siragusa S; Sottilotta G; Tosetto A; Piscitelli L; Villa MR; Zanon E; Finardi A; Schiavetti I; Vaccari D; Castaman G
Haemophilia; 2023 Jan; 29(1):135-144. PubMed ID: 36423202
[TBL] [Abstract][Full Text] [Related]
4. High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice.
Mancuso ME; Oldenburg J; Boggio L; Kenet G; Chan A; Altisent C; Seifert W; Santagostino E
Haemophilia; 2020 Jul; 26(4):637-642. PubMed ID: 32542961
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B.
Mancuso ME; Lubetsky A; Pan-Petesch B; Lissitchkov T; Nagao A; Seifert W; Li Y; Santagostino E
J Thromb Haemost; 2020 May; 18(5):1065-1074. PubMed ID: 32078256
[TBL] [Abstract][Full Text] [Related]
6. Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.
Oldenburg J; Yan S; Maro G; Krishnarajah G; Tiede A
Curr Med Res Opin; 2020 Jan; 36(1):9-15. PubMed ID: 31469321
[No Abstract] [Full Text] [Related]
7. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
Davis J; Yan S; Matsushita T; Alberio L; Bassett P; Santagostino E
J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
[No Abstract] [Full Text] [Related]
8. Pattern of use and clinical outcomes with rIX-FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real-world study.
Giordano P; Pollio B; Sottilotta G; Biasoli C; Daniele F; De Cristofaro R; Peyvandi F; Villa MR; Castaman G;
Eur J Haematol; 2024 May; 112(5):765-775. PubMed ID: 38223989
[TBL] [Abstract][Full Text] [Related]
9. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.
Kenet G; Chambost H; Male C; Lambert T; Halimeh S; Chernova T; Mancuso ME; Curtin J; Voigt C; Li Y; Jacobs I; Santagostino E;
Thromb Haemost; 2016 Sep; 116(4):659-68. PubMed ID: 27583313
[TBL] [Abstract][Full Text] [Related]
10. Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX-Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective-Prospective Study.
Coppola A; Rivolta GF; Quintavalle G; Matichecchia A; Riccardi F; Rossi R; Benegiamo A; Ranalli P; Coluccio V; Tagliaferri A
J Clin Med; 2024 Mar; 13(5):. PubMed ID: 38592343
[No Abstract] [Full Text] [Related]
11. Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion
Lyseng-Williamson KA
Drugs; 2017 Jan; 77(1):97-106. PubMed ID: 27988873
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study.
Kenet G; Chambost H; Male C; Halimeh S; Lambert T; Li Y; Seifert W; Santagostino E
Thromb Haemost; 2020 Apr; 120(4):599-606. PubMed ID: 32185782
[TBL] [Abstract][Full Text] [Related]
14. Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.
Guillet B; Yan S; Hooper B; Drelich D; Steenkamp J; Tomic R; Mancuso ME
Adv Ther; 2024 Feb; 41(2):649-658. PubMed ID: 38070040
[TBL] [Abstract][Full Text] [Related]
15. Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program.
Laws HJ; Fukutake K; Lopez-Fernandez MF; Li Y; Seifert W; Tagliaferri A
Eur J Haematol; 2023 Aug; 111(2):293-299. PubMed ID: 37232041
[TBL] [Abstract][Full Text] [Related]
16. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.
Santagostino E; Martinowitz U; Lissitchkov T; Pan-Petesch B; Hanabusa H; Oldenburg J; Boggio L; Negrier C; Pabinger I; von Depka Prondzinski M; Altisent C; Castaman G; Yamamoto K; Álvarez-Roman MT; Voigt C; Blackman N; Jacobs I;
Blood; 2016 Apr; 127(14):1761-9. PubMed ID: 26755710
[TBL] [Abstract][Full Text] [Related]
17. Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients.
Pabinger I; Lissitchkov T; Nagao A; Lepatan LM; Li Y; Seifert W; Mancuso ME
Res Pract Thromb Haemost; 2023 May; 7(4):100195. PubMed ID: 37538501
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials.
Astermark J; Wojciechowski P; Aballéa S; Hakimi Z; Nazir J; Klamroth R
J Blood Med; 2021; 12():613-621. PubMed ID: 34285621
[TBL] [Abstract][Full Text] [Related]
19. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Santagostino E
Thromb Res; 2013 Mar; 131 Suppl 2():S7-10. PubMed ID: 23537724
[TBL] [Abstract][Full Text] [Related]
20. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
Nolte MW; Nichols TC; Mueller-Cohrs J; Merricks EP; Pragst I; Zollner S; Dickneite G
J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
